Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line

Dharam P. Chauhan, Qinghua Yang, John M. Carethers, Giancarlo Marra, Christina L. Chang, Sherman M Chamberlain, C. Richard Boland

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We have reported that transfer of chromosome 3 (Chr3) containing a single wild-type copy of the hMLH1 gene into HCT116 colon cancer cells, a cell line deficient in DNA mismatch repair (MMR) activity attributable to inactivating hMLH1 mutations, corrects all of the aspects of the MMR repair-deficient phenotype. We inhibited the expression of the wild-type hMLH1 gene using antisense RNA in HCT116+Chr3 cells to determine if this would result in reversion to the MMR-deficient phenotype. Despite profound inhibition of hMLH1 expression, DNA MMR activity and alkylation sensitivity were not impaired in the antisense-transfected HCT116+Chr3 cells. Additionally, arrest of the cell cycle at the G 2 phase with alkylation damage occurs in these cells, a phenotype associated with MMR proficiency. These results indicate that even with a reduction in the expression of hMLH1 protein below the limits of detection by Western blotting, DNA MMR activity remained fully functional (by direct DNA MMR activity assay). We would speculate that hMLH1 is expressed in substantially greater abundance than would be minimally necessary for DNA MMR and that minor reductions in the expression of this protein would not be sufficient to permit DNA MMR dysfunction. Alternatively, Chr3 may contain a second hMLH1 homologue that might overlap with the function of hMLH1.

Original languageEnglish (US)
Pages (from-to)3827-3831
Number of pages5
JournalClinical Cancer Research
Volume6
Issue number10
StatePublished - Jan 1 2000

Fingerprint

DNA Mismatch Repair
Chromosomes, Human, Pair 3
Cell Line
Alkylation
Phenotype
Antisense RNA
Cell Cycle Checkpoints
Colonic Neoplasms
Genes
Limit of Detection
Proteins
Western Blotting
Mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chauhan, D. P., Yang, Q., Carethers, J. M., Marra, G., Chang, C. L., Chamberlain, S. M., & Boland, C. R. (2000). Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line. Clinical Cancer Research, 6(10), 3827-3831.

Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line. / Chauhan, Dharam P.; Yang, Qinghua; Carethers, John M.; Marra, Giancarlo; Chang, Christina L.; Chamberlain, Sherman M; Boland, C. Richard.

In: Clinical Cancer Research, Vol. 6, No. 10, 01.01.2000, p. 3827-3831.

Research output: Contribution to journalArticle

Chauhan, DP, Yang, Q, Carethers, JM, Marra, G, Chang, CL, Chamberlain, SM & Boland, CR 2000, 'Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line', Clinical Cancer Research, vol. 6, no. 10, pp. 3827-3831.
Chauhan DP, Yang Q, Carethers JM, Marra G, Chang CL, Chamberlain SM et al. Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line. Clinical Cancer Research. 2000 Jan 1;6(10):3827-3831.
Chauhan, Dharam P. ; Yang, Qinghua ; Carethers, John M. ; Marra, Giancarlo ; Chang, Christina L. ; Chamberlain, Sherman M ; Boland, C. Richard. / Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 10. pp. 3827-3831.
@article{c205cbbdcb8146659e0cba13c6502327,
title = "Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line",
abstract = "We have reported that transfer of chromosome 3 (Chr3) containing a single wild-type copy of the hMLH1 gene into HCT116 colon cancer cells, a cell line deficient in DNA mismatch repair (MMR) activity attributable to inactivating hMLH1 mutations, corrects all of the aspects of the MMR repair-deficient phenotype. We inhibited the expression of the wild-type hMLH1 gene using antisense RNA in HCT116+Chr3 cells to determine if this would result in reversion to the MMR-deficient phenotype. Despite profound inhibition of hMLH1 expression, DNA MMR activity and alkylation sensitivity were not impaired in the antisense-transfected HCT116+Chr3 cells. Additionally, arrest of the cell cycle at the G 2 phase with alkylation damage occurs in these cells, a phenotype associated with MMR proficiency. These results indicate that even with a reduction in the expression of hMLH1 protein below the limits of detection by Western blotting, DNA MMR activity remained fully functional (by direct DNA MMR activity assay). We would speculate that hMLH1 is expressed in substantially greater abundance than would be minimally necessary for DNA MMR and that minor reductions in the expression of this protein would not be sufficient to permit DNA MMR dysfunction. Alternatively, Chr3 may contain a second hMLH1 homologue that might overlap with the function of hMLH1.",
author = "Chauhan, {Dharam P.} and Qinghua Yang and Carethers, {John M.} and Giancarlo Marra and Chang, {Christina L.} and Chamberlain, {Sherman M} and Boland, {C. Richard}",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
pages = "3827--3831",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line

AU - Chauhan, Dharam P.

AU - Yang, Qinghua

AU - Carethers, John M.

AU - Marra, Giancarlo

AU - Chang, Christina L.

AU - Chamberlain, Sherman M

AU - Boland, C. Richard

PY - 2000/1/1

Y1 - 2000/1/1

N2 - We have reported that transfer of chromosome 3 (Chr3) containing a single wild-type copy of the hMLH1 gene into HCT116 colon cancer cells, a cell line deficient in DNA mismatch repair (MMR) activity attributable to inactivating hMLH1 mutations, corrects all of the aspects of the MMR repair-deficient phenotype. We inhibited the expression of the wild-type hMLH1 gene using antisense RNA in HCT116+Chr3 cells to determine if this would result in reversion to the MMR-deficient phenotype. Despite profound inhibition of hMLH1 expression, DNA MMR activity and alkylation sensitivity were not impaired in the antisense-transfected HCT116+Chr3 cells. Additionally, arrest of the cell cycle at the G 2 phase with alkylation damage occurs in these cells, a phenotype associated with MMR proficiency. These results indicate that even with a reduction in the expression of hMLH1 protein below the limits of detection by Western blotting, DNA MMR activity remained fully functional (by direct DNA MMR activity assay). We would speculate that hMLH1 is expressed in substantially greater abundance than would be minimally necessary for DNA MMR and that minor reductions in the expression of this protein would not be sufficient to permit DNA MMR dysfunction. Alternatively, Chr3 may contain a second hMLH1 homologue that might overlap with the function of hMLH1.

AB - We have reported that transfer of chromosome 3 (Chr3) containing a single wild-type copy of the hMLH1 gene into HCT116 colon cancer cells, a cell line deficient in DNA mismatch repair (MMR) activity attributable to inactivating hMLH1 mutations, corrects all of the aspects of the MMR repair-deficient phenotype. We inhibited the expression of the wild-type hMLH1 gene using antisense RNA in HCT116+Chr3 cells to determine if this would result in reversion to the MMR-deficient phenotype. Despite profound inhibition of hMLH1 expression, DNA MMR activity and alkylation sensitivity were not impaired in the antisense-transfected HCT116+Chr3 cells. Additionally, arrest of the cell cycle at the G 2 phase with alkylation damage occurs in these cells, a phenotype associated with MMR proficiency. These results indicate that even with a reduction in the expression of hMLH1 protein below the limits of detection by Western blotting, DNA MMR activity remained fully functional (by direct DNA MMR activity assay). We would speculate that hMLH1 is expressed in substantially greater abundance than would be minimally necessary for DNA MMR and that minor reductions in the expression of this protein would not be sufficient to permit DNA MMR dysfunction. Alternatively, Chr3 may contain a second hMLH1 homologue that might overlap with the function of hMLH1.

UR - http://www.scopus.com/inward/record.url?scp=0033760356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033760356&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 3827

EP - 3831

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -